「th」の検索結果
185件：76～80件目を表示
-
千寿製薬株式会社
新闻 2026年04月06日 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF） 2025年12月22日 Obtained manufacturing and marketing approval in...
http://www.senju.co.jp/chinese/ -
ida Pharmaceutical Co., Ltd. Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential c...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
ida Pharmaceutical Co., Ltd. Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential c...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
h 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Sh...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307.pdf -
お知らせ | 千寿製薬株式会社
2026年04月06日 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF） 2025年12月22日 Obtained manufacturing and marketing approval in Ja...
http://www.senju.co.jp/chinese/news/